Assouline S, Michaelis LC, Othus M, Hay AE, et al. A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of Leuk Lymphoma 2022 Dec 14:1-5. doi: 10.1080/10428194.2022.2148212.
PMID: 36517990